Piper Sandler Starts Coverage on Day One (DAWN) with Overweight Rating

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is one of the Top 10 Stocks Under $10 That Could Triple. On August 19, Piper Sandler started coverage of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) with an Overweight rating and set a price target of $25.

Piper Sandler noted that investor sentiment has weakened after the first two earnings reports of 2025 from Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) first two earnings reports of 2025. This has been caused mainly because of concerns about a possible plateauing of OJEMDA (tovorafenib) about a year after its launch.

The research firm described the recent stock decline as “overdone.” Piper Sandler believes that the early slowdown in OJEMDA’s performance can be attributed to the unique characteristics of its cancer indication. Prescribing physicians can be disinclined to take risks and adopt new therapies more slowly.

While growth may take longer than some investors expected, Piper Sandler is confident that OJEMDA’s strong clinical data will support solid long-term market penetration for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN).

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is a biopharmaceutical company focused on developing and commercializing first- or best-in-class medicines for pediatric and adult cancers.

While we acknowledge the potential of DAWN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Hot Mid Cap Stocks to Buy Now and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.